Quote | Ventyx Biosciences Inc. (NASDAQ:VTYX)
Last: | $2.14 |
---|---|
Change Percent: | 0.88% |
Open: | $2.24 |
Close: | $2.14 |
High: | $2.24 |
Low: | $2.13 |
Volume: | 625,675 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Ventyx Biosciences Inc. (NASDAQ:VTYX)
2024-07-01 12:39:36 ET Summary Ventyx Biosciences, Inc. is focusing on advancing VTX3232 for obesity and Parkinson's, with early but promising preclinical results in obesity. The drug VTX3232 has shown potential in preclinical trials, but its application in Parkinson’s face...
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
Message Board Posts | Ventyx Biosciences Inc. (NASDAQ:VTYX)
Subject | By | Source | When |
---|---|---|---|
just the news we needed | DewDiligence | investorshub | 07/02/2023 2:16:23 AM |
Price now up | crudeoil24 | investorshub | 06/13/2023 7:26:13 PM |
just the news we needed | crudeoil24 | investorshub | 06/12/2023 8:45:23 AM |
Ventyx Biosciences, Inc. (Nasdaq: $VTYX) (Ventyx), a clinical-stage | crudeoil24 | investorshub | 09/19/2022 4:15:16 PM |
znewcar1: VTYX 64% v15,6M c38.11 f50,9M H41.29 ML16.91 off the 20dma@19.73 | znewcar1 | investorshangout | 09/13/2022 1:57:39 AM |
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...